Exploring Innovation: Recent Approvals and Novel Approaches to Psoriasis Treatment

Bimekizumab, a newly approved biologic for psoriasis, differs from existing biologics in that it blocks both IL-17A and IL-17F. This dual mechanism of action distinguishes it from previous IL-17 blockers, which targeted IL-17A alone. Clinical trials comparing bimekizumab to other biologics demonstrated superior efficacy in achieving complete clearance (PASI-100) and faster onset of response (PASI-75 at week four). In terms of side effects, bimekizumab, like other IL-17 blockers, may cause oral candidiasis. However, most cases are mild to moderate and manageable with treatment. Patients typically tolerate the medication well, and candidiasis rarely leads to discontinuation of treatment. While clinical trial patients may differ from real-world patients in terms of comorbidities, real-world experiences have shown that patients often prioritize the benefits of bimekizumab over the inconvenience of managing candidiasis.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.